Valuation: Arvinas, Inc.

Market Cap 505M 451M 416M 377M 706M 47.92B 718M 5.01B 1.98B 25.11B 1.89B 1.85B 79.15B P/E 2026 *
-343x
P/E 2027 * -2.22x
Enterprise Value 54.04M 48.26M 44.58M 40.4M 75.58M 5.13B 76.83M 536M 212M 2.69B 203M 198M 8.47B EV / Sales 2026 *
0.18x
EV / Sales 2027 * 3.08x
Free-Float
79.97%
Yield 2026 *
-
Yield 2027 * -
1 day-5.51%
1 week+4.16%
Current month-6.14%
1 month-7.28%
3 months-10.59%
6 months-30.33%
Current year-38.79%
1 week 6.95
Extreme 6.95
7.79
1 month 6.74
Extreme 6.74
8.04
Current year 6.74
Extreme 6.74
14.51
1 year 6.74
Extreme 6.74
14.51
3 years 5.9
Extreme 5.9
53.08
5 years 5.9
Extreme 5.9
97.33
10 years 5.9
Extreme 5.9
108.46
Manager TitleAgeSince
Chief Executive Officer 47 12/02/2026
Director of Finance/CFO 56 24/06/2024
Chief Tech/Sci/R&D Officer 58 17/06/2024
Director TitleAgeSince
Chairman 66 15/06/2023
Director/Board Member 65 01/07/2018
Chairman 67 12/02/2026
Date Insider Type Main position Quantity % Market Cap. Importance
21/05/26 Sell

Chief Executive Officer

-2,209 0.0035%
11/05/26 Sell

Chief Financial Officer

-11,139 0.0174%
11/05/26 Sell

Chief Technology Officer

-11,108 0.0174%
Change 5-day change 1-year change 3-year change Capi.($)
-5.38%+4.16%-20.74%-50.10% 505M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+7.50%+11.01%+73.48% 54.89B
+0.57%+4.60%+10.07%+92.86% 53.28B
+0.22%+4.38%+26.69%+51.65% 45.81B
-1.16%+2.46%+21.97%+124.11% 43.46B
-0.34%+5.85%+252.49%+926.26% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+5.68%+36.43%+27.54% 23.76B
Average -0.30%+1.08%+42.37%+137.29% 38.24B
Weighted average by Cap. +0.37%+0.56%+47.66%+159.55%

Financials

2026 *2027 *
Net sales 296M 264M 244M 221M 414M 28.11B 421M 2.94B 1.16B 14.73B 1.11B 1.09B 46.43B 64.19M 57.32M 52.96M 47.99M 89.78M 6.09B 91.27M 637M 252M 3.19B 241M 236M 10.07B
Net income -666K -595K -550K -498K -932K -63.26M -947K -6.62M -2.62M -33.14M -2.5M -2.45M -104M -248M -221M -204M -185M -347M -23.53B -352M -2.46B -974M -12.33B -930M -910M -38.86B
Net Debt -451M -403M -372M -337M -630M -42.79B -641M -4.47B -1.77B -22.42B -1.69B -1.66B -70.68B -307M -274M -253M -229M -429M -29.13B -436M -3.05B -1.21B -15.26B -1.15B -1.13B -48.11B
Projected Income Statement - Annual - Arvinas, Inc.
Logo Arvinas, Inc.
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Employees
246
Date Price Change Volume
23/10/26 $7.260 -5.96% 413,970
22/10/26 $7.720 +2.18% 620,196
21/10/26 $7.555 -1.37% 653,595
20/10/26 $7.660 +5.51% 540,851
19/10/26 $7.260 +4.16% 795,636
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Arvinas, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
7.720USD
Average target price
13.93USD
Spread / Average Target
+80.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arvinas, Inc.
  1. Stock Market
  2. Stocks
  3. ARVN Stock